# Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

> **NCT03778346** · PHASE1 · UNKNOWN · sponsor: **The Sixth Affiliated Hospital of Wenzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- RRMM

## Interventions

- **BIOLOGICAL:** CAR-T therapy in Relapsed/Refractory multiple myeloma

## Key facts

- **NCT ID:** NCT03778346
- **Lead sponsor:** The Sixth Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-15
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03778346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03778346, "Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03778346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*